Vanda Pharmaceuticals Inc. (VNDA) — Financial statements
Income statement, balance sheet, and cash flow for Vanda Pharmaceuticals Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 216↑8.7% | 199↑3.2% | 193↓24.3% | 254↓5.3% | 269 | |
| Cost of Revenue | 13↑15.3% | 11↓23.5% | 15↓39.1% | 24↓5.3% | 26 | |
| Gross Profit | 203↑8.3% | 187↑5.4% | 178↓22.7% | 230↓5.3% | 243 | |
| Operating Expenses | ||||||
| R&D Expenses | 109↑46.8% | 74↓3.1% | 77↓10.4% | 86↑13.8% | 75 | |
| General & Administrative Expenses | 0.00↓100.0% | 145↑28.6% | 112↓16.1% | 134↑14.1% | 117 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 2↑280.0% | 0.50↓80.8% | 3↓61.2% | 7 | |
| SG&A Expenses | 238↑62.5% | 146↑29.7% | 113↓17.3% | 136↑10.0% | 124 | |
| Other Expenses | 7↓3.7% | 7↑248.0% | 2↑37.9% | 2↑2.6% | 1 | |
| Operating Expenses | 354↑55.3% | 228↑18.9% | 192↓14.3% | 224↑11.4% | 201 | |
| Total Costs & Expenses | 367↑53.4% | 239↑15.9% | 207↓16.7% | 248↑9.5% | 227 | |
| Operating Results | ||||||
| Operating Income | -151↓271.8% | -41↓191.4% | -14↓320.4% | 6↓85.0% | 42 | |
| Depreciation & Amortization | 12↑46.5% | 8↑170.2% | 3↑10.1% | 3↓3.8% | 3 | |
| EBITDA | -139↓328.1% | -33↓197.3% | -11↓220.7% | 9↓79.9% | 45 | |
| EBIT | -151↓271.8% | -41↓191.4% | -14↓320.4% | 6↓85.0% | 42 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.20 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.20 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 13↓29.4% | 18↓12.6% | 20↑308.2% | 5↑2398.0% | 0.20 | |
| Income Before Tax | -139↓504.9% | -23↓461.6% | 6↓43.9% | 11↓73.3% | 42 | |
| Income Tax Expense | 82↑2135.0% | -4↓205.0% | 4↓23.8% | 5↓45.5% | 9 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -220↓1066.5% | -19↓853.3% | 3↓60.0% | 6↓81.1% | 33 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -220↓1066.5% | -19↓853.3% | 3↓60.0% | 6↓81.1% | 33 | |
| Bottom-Line Net Income | -220↓1066.5% | -19↓853.3% | 3↓60.0% | 6↓81.1% | 33 | |
| EPS (Basic) | -3.74↓1068.8% | -0.32↓832.3% | 0.04↓60.3% | 0.11↓81.7% | 0.60 | |
| EPS (Diluted) | -3.74↓1068.8% | -0.32↓833.9% | 0.04↓60.4% | 0.11↓81.0% | 0.58 | |
| Weighted Average Shares | 59↑1.3% | 58↑1.3% | 57↑1.6% | 56↑1.6% | 56 | |
| Weighted Average Diluted Shares | 59↑1.3% | 58↑1.0% | 58↑1.0% | 57↑0.1% | 57 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.